Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 16/20 | 0.37 |
| ▸ | PLK2 | Q9NYY3 | 13/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | TAF1 | P21675 | 2/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204238 | 0.85 | PIP4K2A (0.40) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL1202610 | 0.78 | PLK1 (0.53) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL16405219 | 0.77 | BRD4 (0.50) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL31098067 | 0.76 | BRD4 (0.49) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL10453083 | 0.76 | PIP4K2A (0.45) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL3672005 | 0.76 | PLK1 (0.40) | PIP4K2APIP4K2BPLK1PLK3BRD4 | |
| SCHEMBL10098695 | 0.76 | PLK1 (0.40) | PIP4K2APIP4K2BPLK1PLK3BRD4 | |
| SCHEMBL6840359 | 0.76 | PRKDC (0.45) | PIP4K2APIP4K2BPLK1PLK3BRD4 | |
| SCHEMBL4515284 | 0.75 | PIP4K2A (0.44) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL4080282 | 0.75 | PIP4K2A (0.44) | PIP4K2APIP4K2BPLK1PLK2PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | disclosed |
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PIP4K2A 679/4885PIP4K2B 579/4885PLK1 355/4885 |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PIP4K2A 708/4885PIP4K2B 579/4885PLK1 349/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PIP4K2A 219/4885PIP4K2B 168/4885PLK1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.